BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38577608)

  • 1. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
    Zheng Y; Sun H; Yang S; Liu W; Jiang G
    J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.
    Zuo Y; Leng G; Leng P
    Pathol Oncol Res; 2023; 29():1610899. PubMed ID: 37143472
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and validation of the molecular subtype and prognostic signature for clear cell renal cell carcinoma based on neutrophil extracellular traps.
    Quan J; Huang B
    Front Cell Dev Biol; 2022; 10():1021690. PubMed ID: 36523511
    [No Abstract]   [Full Text] [Related]  

  • 4. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
    Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
    J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of Molecular Subtype and Prognostic Signature for Bladder Cancer Based on Neutrophil Extracellular Traps.
    Tu Y; Mao Z
    Cancer Invest; 2023 Apr; 41(4):354-368. PubMed ID: 36762827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A N
    Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
    J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neutrophil extracellular traps-associated lncRNA signature predicts the clinical outcomes in patients with lung adenocarcinoma.
    Ding W; Li B; Zhang Y; He L; Su J
    Front Genet; 2022; 13():1047231. PubMed ID: 36419832
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic value of neutrophil extracellular trap signature in clear cell renal cell carcinoma.
    Li R; Jiang X; Wang P; Liu X
    Front Oncol; 2023; 13():1205713. PubMed ID: 37519809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neutrophil extracellular traps-related gene signature predicts the prognosis of glioblastoma multiforme.
    Sun G; Liu W
    Folia Neuropathol; 2024; 62(1):59-75. PubMed ID: 38174685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Six-gene Prognostic Model Based on Neutrophil Extracellular Traps (NETs)-related Gene Signature for Lung Adenocarcinoma.
    Mo G; Long X; Cao L; Tang Y; Yan Y; Guo T
    Comb Chem High Throughput Screen; 2024 Feb; ():. PubMed ID: 38357943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
    Li L; Chen D; Chen X; Zhu J; Bao W; Li C; Miao F; Feng R
    PeerJ; 2024; 12():e16850. PubMed ID: 38562999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
    Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
    Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. tRNA-Derived RNA Fragments Are Novel Biomarkers for Diagnosis, Prognosis, and Tumor Subtypes in Prostate Cancer.
    Liu W; Yu M; Cheng S; Zhou X; Li J; Lu Y; Liu P; Ding S
    Curr Oncol; 2023 Jan; 30(1):981-999. PubMed ID: 36661724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
    Fei H; Chen X
    Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
    Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.
    Ye C; Qin S; Qiu S; Zhao L; Miao J; Chen Y; Zhou T
    Transl Androl Urol; 2022 Dec; 11(12):1691-1705. PubMed ID: 36632155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning framework develops neutrophil extracellular traps model for clinical outcome and immunotherapy response in lung adenocarcinoma.
    Han AX; Long BY; Li CY; Huang DD; Xiong EQ; Li FJ; Wu GL; Liu Q; Yang GB; Hu HY
    Apoptosis; 2024 Mar; ():. PubMed ID: 38519636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
    Xu Z; Chen S; Zhang Y; Liu R; Chen M
    Front Immunol; 2022; 13():869759. PubMed ID: 35603206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.